Mohebbi Sadra, Khani Yashar, Amiri Amirhossein, Arab Amirreza, Mahmoudi Zarandi Marzieh, Imani Zeinab, Dadgostar Amir, Mehrvar Amir
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Orthop Surg Res. 2025 Jul 8;20(1):623. doi: 10.1186/s13018-025-06017-2.
This systematic review aimed to compare the cost-effectiveness of robotic-assisted unicompartmental knee arthroplasty (rUKA) with manual UKA (mUKA) for patients who have isolated unicompartmental knee osteoarthritis (OA).
A systematic review was conducted following PRISMA guidelines, searching databases including PubMed, Scopus, Embase, and Web of Science up to January 2025. Studies comparing the cost-effectiveness of rUKA and mUKA, including cohort studies, case-control studies, clinical trials, and Markov models, were eligible for inclusion in this study. There were no restrictions. Independent reviewers conducted the screening, data extraction, and quality assessment of the studies, and any resolved conflicts were discussed and referred to the corresponding reviewer for resolution. The National Institute of Health (NIH) tools were utilized for quality assessment of the cohort studies and RCTs. Qualitative synthesis was performed due to methodological heterogeneity. Also, the protocol of this study was registered prospectively on the PROSPERO with registration number CRD420250645008.
Eight studies, including four Markov and four non-Markov from the US and UK, were included in the study. The rUKA procedure showed higher initial costs but improved quality-adjusted life years (QALYs) and lower revision rates compared to mUKA. Incremental cost-effectiveness ratios (ICERs) ranged from £1,238 (approximately $1672) to $47,180 per QALY, consistently below country-specific thresholds, indicating cost-effectiveness, particularly in high-volume centers. Long-term follow-up further supported rUKA, with notable cost savings.
Despite higher upfront costs, rUKA appears to be cost-effective compared to mUKA, driven by reduced revisions and enhanced outcomes, especially in high-volume settings and over extended follow-up periods.
本系统评价旨在比较机器人辅助单髁膝关节置换术(rUKA)与手动单髁膝关节置换术(mUKA)对孤立性单髁膝关节骨关节炎(OA)患者的成本效益。
按照PRISMA指南进行系统评价,检索截至2025年1月的PubMed、Scopus、Embase和Web of Science等数据库。比较rUKA和mUKA成本效益的研究,包括队列研究、病例对照研究、临床试验和马尔可夫模型,均符合纳入本研究的条件。无限制条件。由独立 reviewers 对研究进行筛选、数据提取和质量评估,任何有争议的问题均进行讨论并提交给相应的 reviewer 解决。使用美国国立卫生研究院(NIH)工具对队列研究和随机对照试验进行质量评估。由于方法学异质性,进行了定性综合分析。此外,本研究方案已在PROSPERO上进行前瞻性注册,注册号为CRD420250645008。
本研究纳入了8项研究,其中4项来自美国和英国的马尔可夫模型研究和4项非马尔可夫模型研究。与mUKA相比,rUKA手术的初始成本更高,但质量调整生命年(QALY)有所改善,翻修率更低。增量成本效益比(ICER)每QALY从1238英镑(约合1672美元)到47180美元不等,始终低于各国特定阈值,表明具有成本效益,特别是在高容量中心。长期随访进一步支持rUKA,可显著节省成本。
尽管前期成本较高,但与mUKA相比,rUKA似乎具有成本效益,这得益于翻修减少和结果改善,特别是在高容量环境和长期随访中。